ELECTRA THERAPEUTICS INC
ETRA
9.16
-0.66
-6.72%
ELECTRA THERAPEUTICS INC
US · ETRA
#3672 by market cap
Listed 2026
9.16
-0.66
-6.72%
Live - 5344 symbols - heartbeat 295s ago
· 2026-10-08 07:46
Pre-market
8.81
-3.82%
After-hours
9.16
0.00%
- Market cap
- 559.68M
- P/E (TTM)i
- -5.88
- P/Bi
- -2.55
- EPSi
- -1.01
- Div yieldi
- 0.00%
- 52W posi
- 4%
Reader sentiment
Are you bullish or bearish on ETRA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 7.05M | 11.50M |
| Research & development | 19.27M | 50.39M |
| Operating profit | -26.32M | -61.89M |
| Pretax profit | -24.79M | -61.98M |
| Tax | -- | -- |
| Net profit | -24.79M | -61.98M |
| Basic EPS | -1 | -2 |
| Diluted EPS | -0.63 | -1.80 |
| Line item | 2025-12 | 2026-06 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | -- | -- |
| Research & development | -- | -- |
| Operating profit | -- | -- |
| Pretax profit | -- | -- |
| Tax | -- | -- |
| Net profit | -- | -- |
| Basic EPS | -- | -- |
| Diluted EPS | -- | -- |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 19.42M | 95.49M |
| Cash & ST investments | 15.79M | 86.52M |
| Inventory | -- | -- |
| Total assets | 19.42M | 99.37M |
| Total current liabilities | 4.20M | 9.73M |
| Short-term debt | -- | 605.00K |
| Long-term debt | -- | -- |
| Total liabilities | 122,681,000.00 | 129,694,000.00 |
| Total equity | -103.26M | -30.33M |
| Retained earnings | -111.00M | -172.98M |
| Line item | 2025-12 | 2026-06 |
|---|---|---|
| Total current assets | 95.49M | 100.36M |
| Cash & ST investments | 86.52M | 97.73M |
| Inventory | -- | -- |
| Total assets | 99.37M | 106.50M |
| Total current liabilities | 9.73M | 13.63M |
| Short-term debt | 605.00K | 827.00K |
| Long-term debt | -- | -- |
| Total liabilities | 129,694,000.00 | 133,268,000.00 |
| Total equity | -30.33M | -26.77M |
| Retained earnings | -172.98M | -221.89M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -26.00M | -60.48M |
| Depreciation & amortization | 0 | 61.00K |
| Free cash flow | -26.00M | -61.22M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 14.79M | 33.01M |
| Line item | 2025-12 | 2026-06 |
|---|---|---|
| Operating cash flow | -- | -- |
| Depreciation & amortization | -- | -- |
| Free cash flow | -- | -- |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | -- | -- |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -127.63 | -104.35 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 4.63 | 9.82 |
| Quick ratioi | 3.78 | 8.92 |
| Debt / assetsi | 0.00 | 2.10 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -42.25 |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-12 | 2026-06 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -104.35 | -89.39 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 9.82 | 7.37 |
| Quick ratioi | 8.92 | 7.19 |
| Debt / assetsi | 2.10 | 1.86 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -42.25 | -76.33 |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
Quote time 2026-10-08 07:46:40 · For reference only, not investment advice and not tailored to your situation.